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Abstract  
Introduction: Seventy percent of an estimated 10 million children less than five years of age in developing countries die each year of acute 
respiratory infections, diarrhoea, measles, malaria, malnutrition or a combination of these conditions. Children living with Human immunodeficiency 
virus (HIV) are at risk of diarrhoea because of drug interactions with antiretroviral therapy and bottle feeding. This may be aggravated by 
malnutrition and other infectious diseases which are frequent in children living with HIV. Objective: to evaluate treatment interventions for 
diarrhoea in HIV infected and exposed children. Methods: A comprehensive search was conducted on 02 June 2016 to identify relevant studies 
for inclusion. We included randomised controlled trials of HIV infected or exposed children under 15 years of age with diarrhoea. Two authors 
independently selected studies for inclusion, assessed risk of bias (RoB) and extracted data using a pre-designed data extraction form. 
Results: We included two studies (Amadi 2002 and Mda 2010) that each enrolled 50 participants. The RoB was assessed as low-risk for both 
included studies. There was no difference in clinical cure and all-cause mortality between nitazoxanide and placebo for cryptosporidial diarrhoea in 
Amadi 2002. In Mda 2010, there was a reduction in duration of hospitalisation in the micronutrient supplement group (P < 0.005) although there 
was no difference in all-cause mortality. Conclusion: There is low certainty evidence on the effectiveness of nitazoxanide for treating 
cryptosporidial diarrhoea and micronutrient supplementation in children with diarrhoea. Adequately powered trials are needed to assess 
micronutrients and nitazoxanide, as well as other interventions, for diarrhoea in HIV-infected and-exposed children. 
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Introduction 
 
It is estimated that over 10 million children in developing countries 
die each year before they reach five years of age. Seventy percent 
of these deaths are due to acute respiratory infections (mostly 
pneumonia), diarrhoea, measles, malaria, or malnutrition or a 
combination of these conditions [1]. Diarrhoeal diseases alone 
account for an estimated 17.5-21% (about 2.5 million) of all deaths 
in children in this age range [2,3]. This high disease burden persists 
despite effective prevention strategies like hand washing [4], 
improved disposal of human feaces [5] and improved quality of 
water [6]. According to the Joint United Nations Program on human 
immunodeficiency virus (HIV) and acquired immune deficiency 
syndrome, (AIDS) 33.3 million people were living with HIV 
worldwide at the end of 2009 and 2.5 million were children [7]. 
Children acquire HIV from their mothers at three distinct periods; 
during intra-uterine life (when the child is in the womb), during 
delivery and during breastfeeding. In addition to these, other 
situations in which HIV transmission can occur, though less 
frequently, are nosocomial transmission (infection during hospital 
care) and sexual abuse. In 2009, an estimated 370 000 children 
contracted HIV during the perinatal and breastfeeding period [7]. 
The risk of transmission during breastfeeding alone is about 10%-
16% while intrauterine and perinatal (during labour and delivery) 
transmission account for 25-40% and 60-75% of infections, 
respectively [8]. However, there has been pronounced progress in 
reducing the incidence and impact of HIV among children younger 
than 15 years due to progress in prevention strategies like 
prevention of mother to child transmission (PMTCT) programs 
through the use of antiretroviral (ARV) drugs. A reflection of these 
efforts is that 32% fewer children were newly infected and 26% 
fewer deaths occurred from AIDS-related conditions among children 
in 2009 compared with 2004 [7]. Children who are considered HIV-
exposed include infants who are born to HIV infected mothers 
and/or breastfeeding from an HIV infected mother. Infection should 
have been excluded in those born to HIV infected mothers (did not 
acquire HIV during intra-uterine life or delivery) and in those who 
were breastfeeding from an HIV infected mother after cessation of 
breast milk. These children are at higher risk of mortality compared 
to children who are not exposed to HIV [9,10]. Findings from 
observational studies estimate that the risk of transmission of the 
HIV virus to the child due to breastfeeding is 14% [11]. PMTCT 
guidelines recommend that children receive anti-retroviral therapy 
(ART) during the entire breastfeeding period, in order to reduce HIV 
transmission [12]. Exclusive breastfeeding has been found to be 
associated with a reduced risk of HIV transmission compared to 
mixed feeding [13]. While an estimated 1.7 million babies have 
been infected with the HIV virus through breast milk, up to 1.5 
million babies die every year because they are not breast fed [14]. 
Some children who are born to HIV positive mothers are fed with 
formula. If safe water and adequate sanitation are not available, 
there is an increased risk of diarrhoeal disease from formula 
feeding. An estimated 88% of diarrhoeal deaths worldwide are 
attributable to unsafe water, inadequate sanitation and poor 
hygiene [15]. Therefore, the risk of transmission through 
breastfeeding has to be weighed against the risk of diarrhoeal 
diseases when choosing a method of feeding in HIV infected 
mothers. Treatment of diarrhoea involves fluid replacement, 
reducing intestinal motility, targeting the causative organism and 
replenishing micronutrients. The basis of rehydration during 
diarrhoea is to replace body water that is lost through frequent 
emission of loose stools. Since electrolytes are also lost along with 
water, several types of glucose-based ORS with different 
compositions and osmolarities are available that can compensate 
this loss. 
  
Consumption of fluids that have high osmolarities can lead to 
secretion of water into the intestines and aggravation of 
dehydration. Decreasing the osmolarity of the ORS solution to 245 
mOsm/l by reducing the concentrations of glucose and salt avoids 
this adverse effect and improves the efficacy of the ORS regimen for 
children with acute non-cholera diarrhoea [16]. A new type of ORS, 
which is a polymer-based ORS, has been shown to decrease the 
duration of diarrhoea among adults with cholera and lower the risk 
of unscheduled use of intravenous fluid, compared with a glucose-
based ORS >310 mOsm/l [17]. Antibiotics for treating specific 
opportunistic infections that cause diarrhoea [8], target the 
causative germs and eradicate them in order to stop the diarrhoeal 
episode. However, this has to be done concurrently with adequate 
rehydration and feeding for optimal recovery. Replacing depleted 
micronutrients (such as Zinc) has a preventive and long-lasting 
impact by reducing the number of episodes of diarrhoea in the 2-3 
months after the supplementation regimen [16]. Other treatment 
interventions like anti motility agents have been shown to benefit 
children with acute diarrhoea [18]. A recent systematic review found 
that probiotics administered in addition to rehydration therapy 
resulted in significant reductions in the duration and severity of 
acute infectious diarrhoea [19], however another review found no 
benefit in persistent diarrhoea [20]. In addition to the above 
management strategies, there are additional considerations for 
children living with HIV in whom there is a potential for drug 
interactions with antiretroviral therapy, the possibility of exclusive 
bottle feeding (hence less breast milk) and the wider variety of 
pathological agents. This may be aggravated by malnutrition and 
other infectious diseases which are frequent in children living with 
HIV. Recent Cochrane reviews confirm the benefit of zinc 
supplementation [21], rehydration via oral hydration solution or 
intravenous solutions and antibiotics for bloody diarrhoea [22-24]. 
However, these reviews do not address subpopulations of HIV 
infected or exposed children, who may be especially vulnerable to 
diarrhoeal disease. Infants and children with HIV/AIDS have 
diarrhoeal disease complicated by immunocompromise, 
malnutrition, gastrointestinal manifestations of primary HIV disease, 
and may be treated with ARV drugs, that are associated with 
gastrointestinal symptoms, among other challenges [25-27]. The 
combination of HIV infection and diarrhoea thus represents a 
complex and challenging situation that is faced by health workers 
worldwide and especially in developing countries. WHO has set 
research on childhood diarrhoea as a priority area in order to meet 
the United Nation's Millennium Development goal of reducing 
childhood mortality by two-thirds between 1990 and 2015 [28]. Also 
recognizing that children with HIV require comprehensive care, 
WHO has initiated a series of systematic reviews that will underlie 
evidence-based recommendations on the prevention and treatment 
of common conditions in HIV-infected and exposed children, 
including diarrhoea [29]. In this review, we intend to summarise the 
evidence and outcomes for the recommended treatment 
interventions for diarrhoea in infants and children with HIV infection 
and exposure. 
  
  
Methods 
 
Details of the methodology used in this systematic review have been 
previously published [30]. In summary, we searched for and 
included randomised controlled trials (RCTs) that enrolled children 
less than 15 years of age who are HIV infected or exposed and who 
have diarrhoea (reported by the carer and confirmed by the health 
professional). HIV-exposed infants are defined as infants born to 
HIV infected mothers and/or breastfeeding from an HIV infected 
mother and in whom infection has been excluded after birth in 
those born to HIV infected mothers (did not acquire HIV during 
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intra-uterine life or delivery) and after cessation of breast milk in 
those who were breastfeeding from an HIV infected mother. 
Children who are HIV-infected were those in whom a laboratory 
diagnosis was made. The primary outcomes were clinical cure 
(defined as cessation of diarrhoeal episodes) and all-cause 
mortality. Secondary outcomes included: hospitalisation due to 
diarrhoea; Severity of diarrhoea (stool output: consistency and 
frequency); mortality due to dehydration from diarrhoea; adverse 
treatment events; and recurrence of diarrhoea. We formulated a 
comprehensive search strategy with the assistance of the HIV/AIDS 
Review Group Trials Search co-coordinator, in order to identify all 
relevant published and unpublished studies. The search period was 
from 1 January 1980 to the 2 of June 2016 and included studies 
conducted in all of countries irrespective of language of publication. 
The first two review authors independently assessed identified 
studies for inclusion, extracted data and conducted risk of bias 
assessment using the criteria outlined in the Cochrane Handbook for 
Systematic Reviews of Interventions [31]. We resolved any 
disagreement through discussion and if required, we consulted the 
third author for a final decision. Study data was entered into review 
manager software [32] for analysis. We assessed the certainty of 
evidence using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach [33]. We defined 
the certainty of evidence for each outcome as the extent to which 
one can be confident that an estimate of effect or association is 
close to the quantity of specific interest [31]. The rating across 
studies has four levels: high, moderate, low or very low. 
Randomised controlled trials are categorised as high certainty but 
can be downgraded; similarly, other types of controlled trials and 
observational studies are categorised as low quality but can be 
upgraded [33]. 
  
  
Results 
 
The results of the search (02 June 2016) are summarised in the 
PRISMA flow diagram (Figure 1). There were 1242 records identified 
using the search strategy. Of these, five were identified as being 
potentially relevant and two randomised controlled trials (Table 1) 
were included following assessment of full text articles. Overall, 
these two studies had a low risk of bias according to the Cochrane 
risk of bias tool (Figure 2). In South Africa, Mda 2010 [34] 
compared micronutrient supplementation to placebo for treating 
HIV-infected children with diarrhoea who were admitted to the 
paediatric ward of the Dr George Mukhari hospital which is a tertiary 
referral institution. Fifty HIV-infected children admitted with 
diarrhoea and aged 4 months to 2 years, were randomised; 24 to 
intervention group and 26 to control group (1 participant in the 
control group was excluded following randomisation). Children who 
had diarrhoea lasting above 72 hours, who had received any 
micronutrient, had any chronic illnesses, or were on antiretroviral 
treatment, were not eligible for inclusion. The second trial, Amadi 
2002 [35], was conducted in Zambia. It included children above one 
year of age with cryptosporidial diarrhoea, whose parents agreed to 
perform an HIV test. The trial was conducted between November 
2000 and July 2001 at the Department of Paediatrics and Child 
Health, University Teaching Hospital, or to any of four urban health 
centres managed by the Lusaka Urban District Health Management 
Board. Fifty HIV-infected children were randomised in a 1:1 ratio to 
either nitazoxanide or placebo. Children who had received any 
antiprotozoal drug within two weeks of enrolment were not included 
in the study. Three studies were excluded from this review. Two 
studies; Amadi 2005 [36] and Luabeya 2007 [37] because of 
ineligible participants and one study, Rollins 2007 [38] because of 
ineligible outcomes. 
  
Effects of interventions 
  
Anti-infective agents: Amadi 2002 was conducted in Zambia and 
compared 5ml (100mg) of 20g/l nitazoxanide oral suspension given 
twice daily for three days to an identical placebo in HIV-infected 
children with diarrhoea due to cryptosporidiosis. There was no 
difference (P value = 1.0) in all-cause mortality between the 
nitazoxanide group 5/25 (20%) and the placebo group 4/24 (17%). 
There were 2/25 (8.0%) children in the nitazoxanide group 
assessed as being clinically cured at day 7 of hospitalisation 
compared to 6/24 (25.0%) in the placebo group (P = 0.14). 
  
Micronutrient supplementation: The effect of short-term 
micronutrient supplementation on diarrhoea was assessed in Mda 
2010. A micronutrient supplement (containing: retinol (300µg), 
thiamine (0.6mg), Riboflavin (o.6mg), Niacin 8mg), Pyridoxine 
(0.6mg), Cobalamine (1 µg), Folic Acid (70 µg), Ascorbic Acid 
(25mg), 1,25 dihydro cholecalciferol (5 µg), α-Tocopherol (7 mg), 
Copper (700 µg), Iron (8mg), Selenium (30 µg) and Zinc (8mg)) 
was compared to an identical placebo and administered as 
crushable tablets once daily for the entire duration of 
hospitalisation. All-cause mortality did not differ between study arms 
with 2/24 (8.3%) in the micronutrient supplement group and 2/26 
(7.7%) in the placebo group. The duration of hospitalisation in the 
micronutrient group (mean (SD) = 7.0 days (4.5)) was shorter (P < 
0.005) than the placebo group (mean(SD) = 8.6 days (5.0)). None 
of the included studies reported on adverse effects of the 
interventions. 
  
  
Discussion 
 
There were no summary effect estimates in this review and the 
results of the studies are provided in a narrative manner. The two 
included trials each investigated different interventions compared to 
placebo in HIV-infected children with diarrhoea. In Amadi 2002, 
nitazoxanide did not reduce all-cause mortality and proportion of 
children clinically cured in HIV-infected children with cryptosporidial 
diarrhoea. On the other hand, there was a reduction in duration of 
hospitalisation in the micronutrient supplement group (P < 0.005) in 
Mda 2010 although there was no difference in all-cause mortality. 
The Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) [33] approach was used to assess the quality of 
evidence in this review. Two comparisons were made, each 
addressed by one included study; nitazoxanide versus placebo for 
Mda 2010 (Table 2) and micronutrients versus placebo for Amadi 
2002 (Table 3). Both included studies were randomised controlled 
trials so we initially qualified the evidence as ´very high´ before 
downgrading by two points for serious imprecision due to the very 
small sample sizes. We therefore concluded that there was low-
certainty evidence that micronutrients are more effective compared 
to placebo for treating HIV-infected children with diarrhoea. We also 
concluded that there was low-certainty evidence in favour of 
nitazoxanide compared to placebo for treating HIV-infected children 
with cryptosporidial diarrhoea. It is likely that these results are due 
to small sample sizes in the included studies, rendering them 
underpowered to detect differences in outcomes between 
intervention groups. If further trials are carried out enabling a larger 
number of participants and events in the study, the estimates of 
intervention effects and the certainty of evidence will likely be 
different. With respect to the generalisability of the results, included 
studies enrolled male and female HIV-infected children in Zambia 
and South Africa. The ages ranged from 4 to 24 months in Mda 
2010 and 12 to 85 months in Amadi 2002. The race, level of 
education and socio-economic status of the participants were not 
reported. Black Africans are the most common racial group while 
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income levels and maternal education could vary significantly 
among individuals in these countries. The findings of this review 
therefore apply to the HIV-infected African children and the effects 
of the interventions might differ in other population subgroups. 
  
  
Conclusion 
 
The low-certainty of evidence from this review implies that health 
care workers treating HIV infected children who have diarrhoea 
should weigh the benefits against the risks when making a decision 
on the use of nitazoxanide or micronutrients. There is a need for 
adequately powered trials assessing micronutrients, nitazoxanide 
and other interventions (e.g. oral rehydration therapy, anti-
diarrhoeal agents and other specific anti-infective agents) for 
diarrhoea in HIV -infected and -exposed children. Furthermore, trials 
in children on ART addressing diarrhoea caused by ART-related drug 
interactions are required since these challenges are specific to this 
population. The two included studies were carried out in tertiary 
hospitals located in South Africa and Zambia which are lower middle 
income countries with a predominantly Black-African population. 
There is therefore a need for trials conducted in other countries or 
continents with participants of different races and socio-economic 
contexts. 
 
What is known about this topic 
 
 Treatment with antiretroviral therapy reduces 
opportunistic infections including those that cause 
diarrhea; 
 Symptomatic treatment of diarrhea with oral rehydration 
therapy and antidiarrhoeal agents can improve disease 
outcome. 
 
What this study adds 
 
 This systematic review conducted following Cochrane 
methodology found that nitazoxanide may make little or 
no difference in HIV-infected children with cryptosporidial 
diarrhea and that micronutrient have little or no effect on 
HIV-infected children with diarrhea; 
 We found no clinical trials on treatment of diarrhea in 
HIV-exposed children so there is a need for further clinical 
trials in this sub-population. 
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Table 2: Summary of findings table for Nitazoxanide versus placebo in HIV-infected and -exposed children with 
cryptosporidial diarrhoea 
Patient or population: HIV-infected and HIV-exposed children with cryptosporidial diarrhoea 
Settings: Tertiary hospital in Zambia 
Intervention: Nitazoxanide versus placebo 
Outcomes 
Illustrative comparative 
risks+ (95% CI) Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments Assumed 
risk 
Corresponding 
risk 
Placebo Nitazoxanide 
Clinical cure 
Last unformed 
stool assessed by 
clinician 
Follow-up: 7 days 
See 
comment 
See comment 
Not 
estimable 
50 
(1 study) 
⊕⊕⊝⊝ 
low1 
N/A 
All-cause 
mortality 
Assessed by 
hospital 
personnel 
Follow-up: 8 days 
See 
comment 
See comment 
Not 
estimable 
50 
(1 study) 
⊕⊕⊝⊝ 
low1 
N/A 
+The basis for the assumed risk is the control group risk across the included studies. The corresponding risk (and its 
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI). 
1 Downgraded by two points for imprecision: only one small study reported on this outcome 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect 
and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect 
and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate 
Table 1: Risk of bias assessment for included studies 
Amadi 2002 
Risk of Bias domain Authors’ judgement Support for judgement 
Random sequence generation Low risk Computer-generated random numbers 
Allocation concealment Low risk 
The drug and placebo were supplied in pre-coded 
containers according to the randomisation code. 
Blinding of participants and 
personnel 
Low risk Identical formulation of drug and placebo was used. 
Blinding of outcome assessors Low risk 
Outcome assessors were not aware of treatment 
assignment. 
Incomplete outcome data Low risk All randomised participants accounted for. 
Selective reporting Low risk All relevant outcomes were reported 
Other bias Low risk No other source of bias identified. 
 Mda 2010     
Risk of Bias domain Authors’ judgement Support for judgement 
Random sequence generation Low risk Computer-generated random numbers 
Allocation concealment Low risk Identical containers labelled by study serial number 
Blinding of participants and 
personnel 
Low risk 
Identical appearance and taste of supplement and placebo 
tablets. 
Blinding of outcome assessors Unclear risk 
No detailed information provided on blinding of outcome 
assessors 
Incomplete outcome data Low risk No loss to follow-up 
Selective reporting Low risk All relevant outcomes were reported 
Other bias Low risk No other source of bias identified. 
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Figure 1: Study flow diagram showing study selection and data extraction 
process at each stage of the review  
Table 3: Summary of findings table for micronutrients versus placebo in HIV-infected and -exposed children with diarrhoea 
Patient or population: HIV-infected and HIV-exposed children with diarrhoea 
Settings: Tertiary referral centre in a peri-urban area of South Africa 
Intervention: Micronutrients versus placebo 
Outcomes 
Illustrative comparative 
risks+ (95% CI) Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Certainty of 
the 
evidence 
(GRADE) 
Comments Assumed 
risk 
Corresponding 
risk 
Placebo Micronutrients 
Clinical cure 
See 
comment 
See comment 
Not 
estimable 
N/A See comment Not measured 
All-cause mortality: 
Assessed by clinician at 
study site 
See 
comment 
See comment 
Not 
estimable 
50 
(1 study) 
⊕⊕⊝⊝ 
low1 
N/A 
Hospitalisation due to 
diarrhoea: 
Measured by medical 
staff as time to cessation 
of diarrhoea 
See 
comment 
See comment 
Not 
estimable 
44 
(1 study) 
⊕⊕⊝⊝ 
low1 
N/A 
+The basis for the assumed risk is the control group risk across the included studies. The corresponding risk (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% 
CI). 
1 Downgraded by two points for imprecision: only one small study reported on this outcome 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may 
change the estimate 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely 
to change the estimate 
Very low quality: We are very uncertain about the estimate 
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Figure 2: Risk of bias summary for included studies according to the Cochrane risk 
of bias domains for randomised controlled trials 
 
 
 
